Edition:
United States

Bayer AG (BAYZF.PK)

BAYZF.PK on OTC Markets Group

122.46USD
16 Feb 2018
Change (% chg)

$2.72 (+2.27%)
Prev Close
$119.74
Open
$119.00
Day's High
$122.46
Day's Low
$119.00
Volume
8,088
Avg. Vol
2,983
52-wk High
$140.21
52-wk Low
$109.89

Latest Key Developments (Source: Significant Developments)

Monsanto Paid $2.5 Million In Cash For CEO
Friday, 16 Feb 2018 05:12pm EST 

Feb 16 (Reuters) - Bayer Ag ::MONSANTO - SPECIAL AWARDS WERE PAID IN CASH ON FEB 13, IN AMOUNT OF $2.5 MILLION FOR CHAIRMAN & CEO AND $250,000 FOR OTHER NAMED EXECUTIVE OFFICERS.  Full Article

Bayer And Mitsui Chemicals Agro Sign Licence Agreement For Novel Fungicide
Thursday, 15 Feb 2018 04:35am EST 

Feb 15 (Reuters) - BAYER AG ::BAYER AND MITSUI CHEMICALS AGRO SIGN LICENCE AGREEMENT FOR NOVEL FUNGICIDE.  Full Article

Bayer's Eylea Wins First Regulatory Approval In China
Tuesday, 13 Feb 2018 04:00am EST 

Feb 13 (Reuters) - Bayer ::SAYS EYLEA APPROVED IN CHINA FOR TREATMENT OF DIABETIC MACULAR EDEMA, FIRST APPROVAL FOR EYLEA IN CHINA.  Full Article

Bayer Says Confident They Fully Address The EU's Concerns
Monday, 5 Feb 2018 05:10am EST 

Feb 5 (Reuters) - Bayer AG ::SAYS SUBMITTED SIGNIFICANT REMEDIES TO THE EUROPEAN COMMISSION ABOUT PROPOSED MONSANTO‍​ DEAL.SAYS CONFIDENT THEY FULLY ADDRESS THE EUROPEAN COMMISSION’S CONCERNS.  Full Article

Monsanto Q1 Earnings Per Share $0.38
Thursday, 4 Jan 2018 08:00am EST 

Jan 4 (Reuters) - Monsanto Co ::Q1 EARNINGS PER SHARE $0.38.Q1 EARNINGS PER SHARE VIEW $0.42 -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE $0.41 FROM CONTINUING OPERATIONS.QTRLY TOTAL NET SALES $2,658 MILLION VERSUS $2,650 MILLION LAST YEAR.-CONTINUES PROGRESS TOWARDS CLOSURE OF MERGER WITH BAYER IN EARLY PART OF 2018​.QTRLY TOTAL SEEDS AND GENOMICS SALES $1,770 MILLION VERSUS $1,848 MILLION LAST YEAR.INTACTA RR2 PRO(TM )SOYBEAN ADOPTION IN SOUTH AMERICA OFF TO A GOOD START IN Q1; ON PACE TO REACH 60 MILLION ACRES IN FY18.QUARTERLY RESULTS BENEFIT FROM HIGHER GLYPHOSATE PRICING.MONSANTO - EXPECTS GROWTH IN ITS PRETAX INCOME FOR FY 2018, BUT DID NOT PROVIDE SPECIFIC FINANCIAL GUIDANCE IN LIGHT OF PENDING COMBINATION WITH BAYER.MONSANTO - BRANDED ORDER MIX SUPPORTS EXPECTATIONS FOR 40 MILLION ACRES OF ROUNDUP READY 2 XTENDSOYBEANS IN FY 2018 IN U.S..MONSANTO SAYS CONTINUES PROGRESS TOWARDS CLOSURE OF MERGER WITH BAYER IN EARLY PART OF 2018.MONSANTO - ‍ EXPECTED GROWTH DRIVERS FOR 2018 ARE CONTINUED IMPROVEMENTS IN PRICING FOR GLYPHOSATE, ADOPTION OF NEW TECHNOLOGIES IN SEEDS AND GENOMICS.MONSANTO - CONTINUE TO EXPECT STRONG ADOPTION OF IMPROVED PRICING FOR GLYPHOSATE TO BE TEMPERED BY CHALLENGING GLOBAL CORN AND SOYBEAN PRICES.Q1 REVENUE VIEW $2.77 BILLION -- THOMSON REUTERS I/B/E/S.MONSANTO SEES ‍BENEFITS RELATED TO ASSET SALES,LICENSING CONTRIBUTIONS TO BE ABOUT 30 PERCENT BELOW ABOUT $350 MILLION PRE-TAX AVERAGE CONTRIBUTION FOR LAST 3 YRS.  Full Article

Bayer Announces Initiation Of Rolling Submission Of NDA In U.S. For Larotrectinib
Wednesday, 20 Dec 2017 06:49am EST 

Dec 20 (Reuters) - BAYER AG ::INITIATION OF ROLLING SUBMISSION OF NDA IN U.S. FOR LAROTRECTINIB FOR TREATMENT OF TRK FUSION CANCERS​.‍COMPLETION OF NDA SUBMISSION EXPECTED IN EARLY 2018​.  Full Article

Bayer's Rivaroxaban Submitted To U.S. FDA For Approval
Monday, 11 Dec 2017 08:33am EST 

Dec 11 (Reuters) - BAYER AG ::RIVAROXABAN SUBMITTED TO U.S. FDA FOR APPROVAL IN PATIENTS WITH CORONARY AND/OR PERIPHERAL ARTERY DISEASE.  Full Article

Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program
Friday, 24 Nov 2017 06:21am EST 

Nov 24 (Reuters) - Nektar Therapeutics :Nektar Therapeutics says estimates that it will incur about $3 million to $4 million of wind-down costs.Nektar Therapeutics - costs related to concluding co’s activities related to Bayer's phase 3 Amikacin Inhale clinical program under 2007 agreement.Nektar Therapeutics - based on discussion with Bayer, Nektar does not expect Bayer to move forward any further with the Amikacin Inhale program.  Full Article

Peptidream announces discovery collaboration agreement with Bayer
Sunday, 19 Nov 2017 10:22pm EST 

Nov 19 (Reuters) - Peptidream Inc <4587.T>:Peptidream announces discovery collaboration agreement with bayer.‍Entered into a multi-target discovery collaboration with Germany-based Bayer AG​.Under terms , co would receive undisclosed upfront payment and research funding.Under terms, co is eligible to receive preclinical, clinical, commercialization milestone payments totaling up to $1.11 billion​.Also eligible to receive royalties on sales of any products that arise from collaboration​.  Full Article

PeptiDream announces discovery collaboration agreement with Bayer AG
Thursday, 16 Nov 2017 03:14am EST 

Nov 16 (Reuters) - PeptiDream Inc <4587.T>:Says it announced today that it has entered into a multi-target discovery collaboration with Germany-based Bayer AG.Under the terms of the agreement, it would receive an undisclosed upfront payment and research funding and is eligible to receive preclinical, clinical, and commercialization milestone payments potentially totaling up to $1.11 billion (124.5 billion yen) .In addition, it is eligible to receive royalties on sales of any products that arise from the collaboration .  Full Article

Photo

Monsanto loses bid to stop Arkansas ban on farm chemical

CHICAGO An Arkansas judge on Friday dismissed a Monsanto Co lawsuit aiming to stop Arkansas from blocking the use of a controversial farm chemical the company makes, dealing a blow to its attempts to increase sales of genetically engineered seeds.